Loading...
Market
First company to announce voluntary price reduction for a Medicare-negotiated drug by end of 2025?
2
Resolution / Starting Odds
Novo Nordisk • 25%
AstraZeneca • 25%
GlaxoSmithKline • 25%
Other • 25%
Press releases or official statements from pharmaceutical companies
Story
Medicare Adds 15 Drugs, Including Ozempic, to Second Round of Price Negotiations
Jan 17, 2025, 01:32 PM
The US government has announced that Medicare will negotiate prices for 15 additional prescription drugs in the second round of negotiations under the Inflation Reduction Act. The list includes Novo Nordisk's Ozempic and Wegovy, popular medications for type 2 diabetes and weight loss. Other drugs selected include Trelegy Ellipta, an asthma treatment, and cancer drugs such as Xtandi and Pomalyst. The negotiations aim to reduce costs for Medicare beneficiaries, with new prices expected to take effect in 2027. This initiative is expected to save the government more than $200 billion over a decade and could save seniors up to $2,000 per year.
View original story
Similar markets
Cigna • 33%
No significant reduction • 1%
CVS • 33%
UnitedHealth • 33%
UnitedHealth Group's OptumRx • 25%
Cigna's Express Scripts • 25%
CVS Health's Caremark • 25%
None by end of 2025 • 25%
Other • 25%
Ozempic • 25%
Wegovy • 25%
Janumet • 25%
Other • 25%
Ozempic • 25%
Wegovy • 25%
Janumet • 25%
None • 1%
CVS Health’s Caremark • 33%
Cigna’s Express Scripts • 33%
UnitedHealth’s OptumRx • 33%
Wegovy • 25%
Ozempic • 25%
Rybelsus • 25%
Other • 25%
Yes • 50%
No • 50%
Novo Nordisk • 25%
AstraZeneca • 25%
Pfizer • 25%
Other • 25%
Johnson & Johnson • 25%
Pfizer • 25%
Other • 25%
Novo Nordisk • 25%
Pomalyst • 25%
Trelegy Ellipta • 25%
Wegovy • 25%
Ozempic • 25%
UnitedHealth • 25%
No settlement • 25%
CVS Health • 25%
Cigna • 25%